Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
about
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitusCurrent use of phosphodiesterase inhibitors in urologycGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?The use of phosphodiesterase 5 inhibitors with concomitant medications.Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives.Adulterated and Counterfeit Male Enhancement Nutraceuticals and Dietary Supplements Pose a Real Threat to the Management of Erectile Dysfunction: A Global Perspective.Tadalafil in the treatment of erectile dysfunction.Sexual counselling for individuals with cardiovascular disease and their partners: a consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP).
P2860
Q24246544-CAD260F3-3EA4-4D92-A03D-3592FB49DADCQ26795512-EE5EE2D2-A858-47E0-91E7-D5DAF81FBD7DQ34244951-5B640AC3-65D4-44AA-9484-7A395E15A631Q35827790-1316596C-4CA0-4A5F-BC36-79818DB0715EQ36689825-94D07673-30C3-4C9C-9898-0ECAFFCE190CQ37321940-2CDA01E8-748A-4B9B-BDF5-ACD030662C72Q37472745-561A5151-B755-45F1-8C19-BE03906B5E69Q37686844-2A6774CF-E832-46C5-9014-DE4E179985CDQ38749357-C7CFBF8D-E6C7-470F-8FD3-13D3A274DF7EQ41978073-AFDA30F2-D020-493D-A853-70C0094C5FF6Q50698078-164A22AC-A903-43A8-8658-EA64CB967D04
P2860
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@ast
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@en
type
label
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@ast
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@en
prefLabel
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@ast
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@en
P1476
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
@en
P2093
Culley C Carson
P304
P356
10.1016/J.AMJCARD.2005.07.010
P407
P577
2005-12-05T00:00:00Z